Join the club for FREE to access the whole archive and other member benefits.

Phase 2 clinical trial of lead drug candidate MYMD-1- a therapy for delaying aging


Key points from article :

Sarcopenia trial shows no evidence of toxicity or safety issues and patients were enrolled in the next higher dose of MYMD-1.

MyMD Pharmaceuticals, Inc.® announced further advancement of Phase 2 clinical trial of lead drug candidate MYMD-1® as a therapy for delaying aging and expanding healthy lifespan.

The trial’s Safety Review Committee has confirmed no safety issues and no toxicity in the prior cohort.

The study investigates the efficacy, tolerability and pharmacokinetics of MYMD-1 in the treatment of chronic inflammation associated with sarcopenia in participants aged 65 years or older.

“Having already demonstrated the drug’s mechanism of action and efficacy in Phase 1 ... expect efficacy data in the second half of 2022", said Chris Chapman, Chief Medical Officer.

TNF-α blockers are the most prescribed drugs by revenue, a global market of approximately $40 billion per year.

NOTE: the multivariate model graph included in the press release appears to be misleading according to Matt Kaeberlein in this Twitter thread where he compares it to the actual survival curve data.


Sarcopenia drug trial shows no evidence of toxicity or safety issues

Mentioned in this article:

Click on resource name for more details.

Chris Chapman

President, Director and Chief Medical Officer at MyMD Pharmaceuticals, Inc.®

Matt Kaeberlein

Professor at University of Washington and chair of the American Aging Association

MyMD Pharmaceuticals

Pharmaceutical company developing novel immunotherapies to extend human lifespan